Literature DB >> 2964269

Sublethal, whole-body ionizing irradiation can be tumor promotive or tumor destructive depending on the stage of development of underlying antitumor immunity.

M Awwad1, R J North.   

Abstract

It was shown that sublethal (500 rads), whole-body gamma-irradiation of mice bearing an established i.d. immunogenic tumor can result, after several days delay, in complete tumor regression and long-term survival, but only if radiation is given after the tumor is established and growing progressively. Exposing mice to the same dose of radiation several hours after tumor cells were implanted resulted, in contrast, in enhanced growth of the primary tumor and in earlier death from systemic disease. Irradiation-induced tumor regression failed to occur in mice that were incapable of generating antitumor immunity, because of having been made T cell deficient by thymectomy and irradiation. Again, irradiation-induced tumor regression could be blocked by infusion of spleen cells from donor mice bearing a well-established tumor. These and previously published results support the view that sublethal, whole-body ionizing irradiation causes tumor regression by preferentially destroying radiosensitive suppressor T cells, thereby enabling the host to generate a therapeutic level of concomitant immunity. It is suggested that the preferential destruction of suppressor cells by irradiation depends on the acquisition, during immunologic induction, of radioresistance by antigen-activated effector T cells, and that this is the reason irradiation causes regression only of established tumors. Not all tumors tested were immunogenic enough to undergo regression in response to gamma-irradiation.

Entities:  

Mesh:

Year:  1988        PMID: 2964269     DOI: 10.1007/bf00199848

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

Review 1.  Ionizing radiation and the immune response.

Authors:  R E Anderson; N L Warner
Journal:  Adv Immunol       Date:  1976       Impact factor: 3.543

2.  In vivo splenic irradiation eradicates suppressor T-cells causing the regression and inhibition of established tumor.

Authors:  W E Enker; J L Jacobitz
Journal:  Int J Cancer       Date:  1980-06-15       Impact factor: 7.396

3.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

Review 4.  Down-regulation of the antitumor immune response.

Authors:  R J North
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

5.  Immunologic defenses against metastases: impairment by excision of an allotransplanted lymphoma.

Authors:  R K Gershon; R L Carter; K Kondo
Journal:  Science       Date:  1968-02-09       Impact factor: 47.728

6.  Growth of a local tumor exerts a specific inhibitory effect on progression of lung metastases.

Authors:  E Gorelik; S Segal; M Feldman
Journal:  Int J Cancer       Date:  1978-05-15       Impact factor: 7.396

7.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

8.  Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population.

Authors:  K E Hellström; I Hellström; J A Kant; J D Tamerius
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

9.  Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.

Authors:  R J North; I Bursuker
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  11 in total

1.  Reduced numbers of CD4+ suppressor cells with subsequent expansion of CD8+ protective T cells as an explanation for the paradoxical state of enhanced resistance to Leishmania in T-cell deficient BALB/c mice.

Authors:  J O Hill
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

2.  Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma.

Authors:  R J North; M Awwad
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

Review 3.  Mechanisms of Normal Tissue Injury From Irradiation.

Authors:  Deborah E Citrin; James B Mitchell
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

4.  Impaired immune regulation after radioiodine therapy for Graves' disease and the protective effect of Methimazole.

Authors:  Sarah Côté-Bigras; Viet Tran; Sylvie Turcotte; Marek Rola-Pleszczynski; Jean Verreault; Diane Rottembourg
Journal:  Endocrine       Date:  2015-12-23       Impact factor: 3.633

5.  The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells.

Authors:  Andrea Balogh; Eszter Persa; Enikő Noémi Bogdándi; Anett Benedek; Hargita Hegyesi; Géza Sáfrány; Katalin Lumniczky
Journal:  Inflamm Res       Date:  2012-10-19       Impact factor: 4.575

6.  Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.

Authors:  M Awwad; R J North
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

7.  T lymphocytes and normal tissue responses to radiation.

Authors:  Dörthe Schaue; William H McBride
Journal:  Front Oncol       Date:  2012-09-19       Impact factor: 6.244

8.  Ionizing radiation selectively reduces skin regulatory T cells and alters immune function.

Authors:  Yu Zhou; Houping Ni; Klara Balint; Jenine K Sanzari; Tzvete Dentchev; Eric S Diffenderfer; Jolaine M Wilson; Keith A Cengel; Drew Weissman
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

Review 9.  A Century of Radiation Therapy and Adaptive Immunity.

Authors:  Dörthe Schaue
Journal:  Front Immunol       Date:  2017-04-11       Impact factor: 7.561

10.  Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment.

Authors:  Slavisa Tubin; Martin Ashdown; Branislav Jeremic
Journal:  Radiat Oncol       Date:  2019-12-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.